Spontaneous reports and pharmacogenetics: The role of the pharmacovigilance centre

Drug Safety

Volumn 32, Issue 4, 2009, Pages 357-358

  Puijenbroek, Eugéne Van ^a   Conemans, Jean ^b   Grootheest, Kees Van ^a  

^a Netherlands Pharmacovigilance Centre Lareb   (Netherlands)

^b Hospital Pharmacy ZANOB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; MIVACURIUM; SUXAMETHONIUM;

BONE MARROW TOXICITY; DISEASE CLASSIFICATION; DRUG SURVEILLANCE PROGRAM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE PERSONNEL; HUMAN; LETTER; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL PRACTICE; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG MONITORING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 65949092560     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932040-00009     Document Type: Letter

References (4)

1. Howland H. Pharmacogenetics and pharmacovigilance. Drug Safety 2009; 32 (3): 265-70
2. Van Puijenbroek EP, Conemans J, Van Grootheest AC. Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands. Drug Saf 2009; 32 (3): 255-64
3. Lehman H, Ryan E. The familial incidence of low pseudocholinesterase levels. Lancet 1956 Jul 21; 271 (6934): 124
4. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26: 186-91